Citations

Clear

3030 citation(s) found for "Susan, M".

Left Ventricular Isovolumetric Relaxation Time Is Prolonged in Fetal Long-QT Syndrome
Clur, Sally-Ann B., Vink, Arja S. , Etheridge, Susan P. , Medina, Pascale G. Robles de, Rydberg, Annika , Ackerman, Michael J. , Wilde, Arthur A.M. , Benson, D. Woodrow , Herberg, Ulrike , Robles de Medina, Pascale G, Wilde, Arthur A, Donofrio, Mary T, Cuneo, Bettina F. , Clur, Sally‐Ann B. , Blom, Nico A. , Donofrio, Mary T.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 13, 2018 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/circep.117.005797 | PMID 29654130 Get It

Background: Long-QT syndrome (LQTS), an inherited cardiac repolarization disorder, is an important cause of fetal and neonatal mortality. Detecting LQTS prenatally is challenging. A fetal heart rate (FHR) less than third percentile for gestational age is specific for LQTS, but the sensitivity is only ≈50%. Left ventricular isovolumetric relaxation time (LVIRT) was evaluated as a potential diagnostic marker for fetal LQTS. Methods and Results: LV isovolumetric contraction time, LV ejection time, LVIRT, cycle length, and FHR were measured using pulsed Doppler waveforms in fetuses. Time intervals were expressed as percentages of cycle length, and the LV myocardial performance index was calculated. Single measurements were stratified by gestational age and compared between LQTS fetuses and controls. Receiver-operator curves were performed for FHR and normalized LVIRT (N-LVIRT). A linear mixed-effect model including multiple measurements was used to analyze trends in FHR, N-LVIRT, and LV myocardial performance index. There were 33 LQTS fetuses and 469 controls included. In LQTS fetuses, the LVIRT was prolonged in all gestational age groups ( P <0.001), as was the N-LVIRT. The best cutoff to diagnose LQTS was N-LVIRT ≥11.3 at ≤20 weeks (92% sensitivity, 70% specificity). Simultaneous analysis of N-LVIRT and FHR improved the sensitivity and specificity for LQTS (area under the curve=0.96; 95% confidence interval, 0.82–1.00 at 21–30 weeks). N-LVIRT, LV myocardial performance index, and FHR trends differed significantly between LQTS fetuses and controls through gestation. Conclusions: The LVIRT is prolonged in LQTS fetuses. Findings of a prolonged N-LVIRT and sinus bradycardia can improve the prenatal detection of fetal LQTS.
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Haeberlein, Samantha Budd , Carrillo, María C. , Hendrix, James A. , Kerchner, Geoff, Margolin, Richard , Maruff, Paul , Tong, Gary, Tome, Maria, Murray, Melissa E. , Nelson, Peter T. , Sano, Mary , Mattsson, Niklas , Sultzer, David L. , Montine, Thomas J. , Jack, Clifford R. , Kolb, Hartmuth C. , Petersen, Ronald C. , Vemuri, Prashanthi , Canniere, Megan Zoschg, Resnick, Susan M. , Romano, Gary, Harten, Argonde C. van , Bain, Lisa J. , Siemers, Eric , Jack, Clifford R , Vemuri, Prashanthi , Murray, Melissa E , Knopman, David S. , Miller, David S. , Schneider, Julie A. , Wolk, David A. , Maruff, Paul

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 563-575

10.1016/j.jalz.2018.03.002 | PMID 29653607 Get It

AbstractThe Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the “A, T, N System” (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Chiang, Angie C.A. , Fowler, Stephanie , Savjani, Ricky R. , Hilsenbeck, Susan G. , Wallace, Clare E. , Cirrito, John R. , Das, Pritam , Jankowsky, Joanna L. , Savjani, Ricky R. , Hilsenbeck, Susan Galloway

Mayo Clinic

Journal of Experimental Medicine | April 6, 2018 | Volume: 215 | Issue: 5 | Pages: 1349-1364

10.1084/jem.20171484 | PMID 29626114 Get It

Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the impact on cellular and cognitive functions affected by Aβ has not been tested. We used a controllable APP transgenic mouse model to test whether combining genetic suppression of Aβ production with passive anti-Aβ immunization improved functional outcomes over either treatment alone. Compared with behavior before treatment, arresting further Aβ production (but not passive immunization) was sufficient to stop further decline in spatial learning, working memory, and associative memory, whereas combination treatment reversed each of these impairments. Cognitive improvement coincided with resolution of neuritic dystrophy, restoration of synaptic density surrounding deposits, and reduction of hyperactive mammalian target of rapamycin signaling. Computational modeling corroborated by in vivo microdialysis pointed to the reduction of soluble/exchangeable Aβ as the primary driver of cognitive recovery.
Multimorbidity and Functional Limitation in Individuals with Heart Failure: A Prospective Community Study
Manemann, Sheila M., Chamberlain, Alanna M. , Roger, Véronique L. , Boyd, Cynthia M. , Weston, Susan A., Jiang, Ruoxiang , Dunlay, Shannon M. , Chamberlain, Alanna M , Cheville, Andrea , Rutten, Lila J. Finney

Mayo Clinic

Journal of the American Geriatrics Society | March 31, 2018 | Volume: 66 | Issue: 6 | Pages: 1101-1107

10.1111/jgs.15336 | PMID 29603724 Get It

Objectives To characterize the individual and combined effects of multimorbidity and functional limitation on healthcare use and mortality in a large, community cohort of individuals with heart failure (HF). Design Prospective cohort study. Setting Eleven southeastern Minnesota counties. Participants Individuals (mean age 74, 54% male) with a first‐ever HF code ( International Classification of Diseases, Ninth Revision code 428 or Tenth Revision code I50) between January 1, 2013 and March 31, 2016 (N=2,692). Measurements Eight activities of daily living measured using a survey on a Likert scale (1=without any difficulty, 5=unable to do; median=8). Participants with a score greater than 8 were categorized as having functional limitation. Multimorbidity was defined as having 2 or more noncardiac comorbidities. Results Twenty‐five percent of participants had neither multimorbidity nor functional limitation, 35% had multimorbidity, 9% had functional limitation, and 31% had both. After adjustment, participants with multimorbidity and functional limitation had greater risks of all outcomes (death: hazard ratio (HR)=4.92, 95% confidence interval (CI)=3.03–8.00; emergency department (ED) visit: HR=3.67, 95% CI=2.94–4.59; hospitalization: HR=3.66, 95% CI=2.85–4.70; outpatient visit: HR=1.73, 95% CI=1.52–1.96) than those with neither. Participants with functional limitation alone had greater risks of death (HR=4.84, 95% CI=2.78–8.43), ED visits (HR=2.35, 95% CI=1.75–3.16), and hospitalizations (HR=2.10, 95% CI=1.52–2.88) but not outpatient visits. Those with multimorbidity alone had similar risks of ED visits and hospitalizations as those with functional limitation alone but were more likely to have outpatient visits (HR=1.50, 95% CI=1.34–1.67). Conclusion Individuals with both multimorbidity and functional limitation have the highest risk of death and healthcare use. Individuals with only functional limitation have similar rates of hospitalizations and ED visits as those with only multimorbidity, underscoring the need to consider both when managing individuals with HF.
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Pinto, Navin , DuBois, Steven G. , Marachelian, Araz , Diede, Scott J. , Taraseviciute, Agne, Bender, Julia Glade , Groshen, Susan , Haas‐Kogan, Daphne A. , Kang, Min H. , Irwin, Meredith S. , Macy, Margaret E. , Villablanca, Judith G. , Reid, Joel M. , Irwin, Meredith S , Macy, Margaret E , Villablanca, Judith G , Tsao-Wei, Denice D , Reynolds, C. Patrick , Matthay, Katherine K. , Park, Julie R. , Glade-Bender, Julia

Mayo Clinic

Pediatric Blood & Cancer | March 31, 2018 | Volume: 65 | Issue: 7 | Pages: No page available

10.1002/pbc.27023 | PMID 29603591 Get It

AbstractBackgroundVorinostat combined with retinoids produces additive antitumor effects in preclinical studies of neuroblastoma. Higher systemic exposures of vorinostat than achieved in pediatric phase I trials with continuous daily dosing are necessary for in vivo increased histone acetylation and cytotoxic activity. We conducted a phase I trial in children with relapsed/refractory neuroblastoma to determine the maximum tolerated dose (MTD) of vorinostat on an interrupted schedule, escalating beyond the previously identified pediatric MTD.MethodsIsotretinoin (cis‐13‐retinoic acid) 80 mg/m2/dose was administered by mouth twice daily on days 1–14 in combination with escalating doses of daily vorinostat up to 430 mg/m2/dose (days 1–4; 8–11) in each 28‐day cycle using the standard 3 + 3 design. Vorinostat pharmacokinetic testing and histone acetylation assays were performed.ResultsTwenty‐nine patients with refractory or relapsed neuroblastoma were enrolled and 28 were evaluable for dose escalation decisions. Median number of cycles completed was two (range 1–15); 11 patients received four or more cycles. Three patients experienced cycle 1 dose‐limiting toxicities. A total of 18 patients experienced grade 3/4 toxicities related to study therapy. The maximum intended dose of vorinostat (430 mg/m2/day, days 1–4; 8–11) was tolerable and led to increased histone acetylation in surrogate tissues when compared to lower doses of vorinostat (P = 0.009). No objective responses were seen.ConclusionsIncreased dose vorinostat (430 mg/m2/day) on an interrupted schedule is tolerable in combination with isotretinoin. This dose led to increased vorinostat exposures and demonstrated increased histone acetylation. Prolonged stable disease in patients with minimal residual disease warrants further investigation.
Developing drugs for treatment of atopic dermatitis in children (≥3 months to
Siegfried, Elaine C. , Jaworski, Jennifer C., Eichenfield, Lawrence F. , Altman, Emily , Arena, Charles, Block, Julie, Boguniewicz, Mark , Chen, Suephy C. , Hanna, Diane , Horii, Kimberly A., Hultsch, Thomas , Lio, Peter , Milner, Joshua D. , Omachi, Theodore A. , Schneider, Lynda C. , Sidbury, Robert , Smith, Timothy W. , Sugarman, Jeffrey, Taha, Sharif, Tofte, Susan, Tollefson, Megha M. , Tom, Wynnis L. , Whitney, Lucinda , Zane, Lee T., Tollefson, Megha, Paller, Amy S. , Hebert, Adelaide Ann , Simpson, Eric Lawrence , Blauvelt, Andrew , Cordoro, Kelly M. , Lee, James , Leung, Donald Y.M. , Schneider, Christine B. , Sugarman, Jeffrey, West, Dennis Paul

Mayo Clinic

Pediatric Dermatology | March 30, 2018 | Volume: 35 | Issue: 3 | Pages: 303-322

10.1111/pde.13452 | PMID 29600515 Get It

AbstractAtopic dermatitis is the most common chronic skin disease, and it primarily affects children. Although atopic dermatitis (AD) has the highest effect on burden of skin disease, no high‐level studies have defined optimal therapy for severe disease. Corticosteroids have been used to treat AD since the 1950s and remain the only systemic medication with Food and Drug Administration approval for this indication in children, despite published guidelines of care that recommend against this option. Several clinical trials with level 1 evidence have supported the use of topical treatments for mild to moderate atopic dermatitis in adults and children, but these trials have had little consistency in protocol design. Consensus recommendations will help standardize clinical development and trial design for children. The Food and Drug Administration issues guidance documents for industry as a source for “the Agency's current thinking on a particular subject.” Although they are nonbinding, industry considers these documents to be the standard for clinical development and trial design. Our consensus group is the first to specifically address clinical trial design in this population. We developed a draft guidance document for industry, Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 months to <18 years of age). This draft guidance has been submitted to the Food and Drug Administration based on a provision in the Federal Register (Good Guidance Practices).
Serum Triamcinolone Levels following Cervical Interlaminar Epidural Injection
Lamer, Tim J. , Dickson, Rozalin R. , Gazelka, Halena M. , Nicholson, Wayne T. , Moeschler, Susan M. , Hooten, W. Michael , Reid, Joel M. , Hooten, W Michael , Lamer, Tim J

Mayo Clinic

Pain Research and Management | March 21, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/8474127 | PMID 29755622 Get It

Background. Cervical interlaminar epidural steroid injections (ESIs) are commonly performed procedures to treat painful cervical radiculopathy, but little is known about the systemic absorption and serum levels of steroids following injection. The primary objective of this study was to investigate the pharmacokinetics of fluoroscopy-guided cervical epidural-administered triamcinolone acetonide in a cohort of patients with cervical radicular pain seeking treatment in a pain medicine clinic.Methods. The study cohort included eight patients undergoing a fluoroscopically guided C7-T1 interlaminar ESI at a pain medicine specialty clinic. Blood was collected prior to the ESI and on days 1, 2, 4, 6, 8, 14, 21, 28, 35, and 42 following the injection. The sample extract was analyzed by tandem mass spectrometry.Results. The terminal elimination half-life of cervical epidural-administered triamcinolone in a noncompartmental analysis was 219 hours. In the noncompartmental analysis, peak triamcinolone concentrations of 5.4 ng/mL were detected within 22.1 hours after administration.Conclusions. The pharmacokinetics of cervical epidural-administered triamcinolone is consistent with our previous study of lumbar ESI, demonstrating that the elimination half-life is longer than that which has been reported following intravenous triamcinolone. The elimination half-life was shorter following cervical ESI than that which has been reported following lumbar ESI.
Germline Lysine-Specific Demethylase 1 ( LSD1/KDM1A ) Mutations Confer Susceptibility to Multiple Myeloma
Wei, Xiaomu , Calvo-Vidal, M. Nieves, Chen, Siwei , Wu, Gang , Revuelta, María V. , Zhang, Jinghui , Walsh, Michael F. , Nichols, Kim E. , Vijai, Joseph , Snyder, Carrie, Vachon, Celine M. , McKay, James , Wang, Shuping , Jayabalan, David , Jacobs, Lauren , Becirovic, Dina, Waller, Rosalie G., Artomov, Mykyta , Viale, Agnès , Patel, Jayeshkumar , Curtin, Karen , Salama, Mohamed E. , Atanackovic, Djordje , Niesvizky, Rubén, Godley, Lucy A. , Churpek, Jane E. , Dumontet, Charles , Lynch, Henry T., Camp, Nicola J. , Offit, Kenneth , Klein, Robert J. , Lipkin, Steven M. , Waller, Rosalie G. , Griffin, R. L. , Joseph, Vijai , Revuelta, Maria , Waller, Rosalie G , Godley, Lucy A , Sun, Jian Hua , Vachon, Celine M. , Waller, Rosalie G., Phillip, Jude M. , Chen‐Kiang, Selina , Landgren, Ola , Slager, Susan L. , Garber, Judy E. , Anderson, Kenneth C. , Daly, Mark J. , Roeder, Robert G. , Mullighan, Charles G. , Yu, Haiyuan , Cerchietti, Leandro C. A. , Wu, Gang , Nichols, Kim E , Griffin, Rosalie , Klein, Robert , Churpek, Jane E , Churpek, Jane

Mayo Clinic

Cancer Research | March 20, 2018 | Volume: 78 | Issue: 10 | Pages: 2747-2759

10.1158/0008-5472.can-17-1900 | PMID 29559475 Get It

Abstract Given the frequent and largely incurable occurrence of multiple myeloma, identification of germline genetic mutations that predispose cells to multiple myeloma may provide insight into disease etiology and the developmental mechanisms of its cell of origin, the plasma cell (PC). Here, we identified familial and early-onset multiple myeloma kindreds with truncating mutations in lysine-specific demethylase 1 (LSD1/KDM1A), an epigenetic transcriptional repressor that primarily demethylates histone H3 on lysine 4 and regulates hematopoietic stem cell self-renewal. In addition, we found higher rates of germline truncating and predicted deleterious missense KDM1A mutations in patients with multiple myeloma unselected for family history compared with controls. Both monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma cells have significantly lower KDM1A transcript levels compared with normal PCs. Transcriptome analysis of multiple myeloma cells from KDM1A mutation carriers shows enrichment of pathways and MYC target genes previously associated with myeloma pathogenesis. In mice, antigen challenge followed by pharmacologic inhibition of KDM1A promoted PC expansion, enhanced secondary immune response, elicited appearance of serum paraprotein, and mediated upregulation of MYC transcriptional targets. These changes are consistent with the development of MGUS. Collectively, our findings show that KDM1A is the first autosomal-dominant multiple myeloma germline predisposition gene providing new insights into its mechanistic roles as a tumor suppressor during post-germinal center B-cell differentiation. Significance: KDM1A is the first germline autosomal dominant predisposition gene identified in multiple myeloma and provides new insights into multiple myeloma etiology and the mechanistic role of KDM1A as a tumor suppressor during post-germinal center B-cell differentiation. Cancer Res; 78(10); 2747–59. ©2018 AACR.